Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07566429 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)

StatusNot Yet Recruiting
PhasePhase 2
SponsorBayer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 15, 2028 → Jun 15, 2029
See other at-risk trials from Bayer

Record History

  1. Primary completion pushed from Dec 15, 2028 to Jun 15, 2029 Start date: Jul 27, 2026 to Jan 25, 2027 · Completion pushed from Jun 15, 2032 to Dec 15, 2032 · Site details revised at 1 of 6 sitesv3 Show 3 more changesShow less
    • Start date: Jul 27, 2026 to Jan 25, 2027
    • Completion pushed from Jun 15, 2032 to Dec 15, 2032
    • Site details revised at 1 of 6 sites
  2. Eligibility criteria shortened, about 2 words Study title expanded, about 1 wordv2 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bayer
131 trials monitored
See 7 trials at risk
Parkinson's Disease
1,435 trials monitored
See 62 trials at risk
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).
Trial Details
NCT Number NCT07566429
Lead Sponsor Bayer
Collaborators: AskBio Inc
Conditions Parkinson Disease
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov